Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®

References

• European Medicines Agency. REMICADE® (infliximab). European Union: London, UK; 2016 Nov 21 [accessed 2017 March 8]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000240/human_med_001023.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Janssen Biotech. REMICADE® (infliximab). Titusville, NJ: Janssen Immunology; 2016 December [accessed 2017 March 8]. http://www.remicade.com
   Google Scholar
• Public Health Services Act. 42 U.S.C. § 262(k)(2)(A)(i)(I)
   Google Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 2015; 25:1325-34; PMID:26263923; https://doi.org/10.1093/glycob/cwv065
   PubMed Web of Science ®Google Scholar
• Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs 2012; 4:326-40; PMID:22531441; https://doi.org/10.4161/mabs.19941
   PubMed Web of Science ®Google Scholar
• Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood 2007; 110(7):2561-4; PMID:17475906; https://doi.org/10.1182/blood-2007-01-070656
   PubMed Web of Science ®Google Scholar
• Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471-8; PMID:18606225; https://doi.org/10.1016/j.coi.2008.06.007
   PubMed Web of Science ®Google Scholar
• Routier FH, Davies MJ, Bergemann K, Hounsell EF. The glycosylation pattern of humanized IgGI antibody (D1.3) expressed in CHO cells. Glycoconj J 1997; 14:201-7; PMID:9111137; https://doi.org/10.1023/A:1018589704981
   PubMed Web of Science ®Google Scholar
• Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, Shitara K, Satoh M. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 2009; 9:58; PMID:19226457; https://doi.org/10.1186/1471-2407-9-58
   PubMed Web of Science ®Google Scholar
• Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 2008; 99:652-65; PMID:17680659; https://doi.org/10.1002/bit.21598
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 2007; 44:1524-34; PMID:17045339; https://doi.org/10.1016/j.molimm.2006.09.005
   PubMed Web of Science ®Google Scholar
• Raju TS, Jordan RE. Galactosylation variations in marketed therapeutic antibodies. MAbs 2012; 4:385-391; PMID:22531450; https://doi.org/10.4161/mabs.19868
   PubMed Web of Science ®Google Scholar
• Butler M, Spearman M. The choice of mammalian cell host and possibilities for glycosylation engineering. Curr Opin Immunol 2014; 30:107-12; PMID:25005678; https://doi.org/10.1016/j.copbio.2014.06.010
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; https://doi.org/10.1074/jbc.M202069200
   PubMed Web of Science ®Google Scholar
• Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11:2327-36; PMID:15788684; https://doi.org/10.1158/1078-0432.CCR-04-2263
   PubMed Web of Science ®Google Scholar
• Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005; 306:151-60; PMID:16219319; https://doi.org/10.1016/j.jim.2005.08.009
   PubMed Web of Science ®Google Scholar
• Schnueriger A, Grau R, Sondermann P, Schreitmueller T, Marti S, Zocher M. Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies. Mol Immunol 2011; 48:1512-7; PMID:21570725; https://doi.org/10.1016/j.molimm.2011.04.010
   PubMed Web of Science ®Google Scholar
• Bergelson S. Biological methods for assessment of Fc effector function of antibodies and Fc-containing molecules [oral presentation]. Presented at: Biopharmaceuticals Emerging Best Practices Association's Fifth Annual Biological Assay Conference; 2012 September 27; Lisbon, Portugal. [accessed 2017 March 8]. http://www.bebpa.org/wp-content/uploads/2012/11/Svetlana-Bergelson-BEBPA-2012-final.pdf
   Google Scholar
• Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ. Physicochemical characterization of Remsima. MAbs 2014; 6(5):1163-77; PMID:25517302; https://doi.org/10.4161/mabs.32221
   PubMed Web of Science ®Google Scholar
• Hong J, Lee Y, Lee C, Eo S, Kim S, Lee N, Park J, Park S, Seo D, Jeong M, et al. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). MAbs 2017; 9(2):364-82; PMID:28005456; https://doi.org/10.1080/19420862.2016.1264550
   PubMed Web of Science ®Google Scholar
• FDA Briefing Document, Arthritis Advisory Committee Meeting. ABP 501-biosimilar candidate to adalimumab. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM511900.pdf
   Google Scholar
• FDA Briefing Document, Arthritis Advisory Committee Meeting. CT-P13, a proposed biosimilar to Remicade (infliximab), Celltrion (BLA 125544). https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm484860.pdf
   Google Scholar